Novartis previously signed an agreement with CellforCure in July to produce CAR-T cell therapies including Kymriah (tisagenlecleucel) – which was the first CAR-T cell therapy approved by the FDA ...

Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.

Senator asks Novartis to explain its payments to Cohen, noting FDA approval of cancer drug Novartis made $1.2 million in payments to Cohen's firm during the time that the FDA was deciding whether ...

Indeed, although chimeric antigen receptor T cell technology has already yielded the first approved single-administration treatments—Kymriah from Novartis and Yescarta from Kite Pharma (now ...

Update (September 19): Although the National Institute for Health and Care Excellence (NICE) decided that Kymriah could be used in young patients with hard-to-treat leukemia, the agency ruled that the ...

The first CAR-T therapy approved by the Food and Drug Administration was Kymriah, made by Novartis, in 2017 for the treatment of pediatric acute lymphoblastic leukemia. A handful more have since ...